AngioDynamics Raises Sales Guidance Again, EPS Loss Range $0.30 to $0.23
AngioDynamics raised full-year net sales guidance for the third straight quarter after delivering sequential revenue growth driven by AlphaVac adoption and Auryon hospital expansion. Despite this, adjusted EPS loss remains at $0.30 to $0.23 reflecting ongoing margin pressure from inflationary and operational costs.
1. Q3 Revenue and Guidance Upside
AngioDynamics delivered sequential revenue growth and raised full-year net sales and adjusted EBITDA guidance for the third quarter in a row, reflecting confidence in product performance and market demand.
2. EPS Loss and Margin Pressures
Management maintained adjusted loss per share guidance of $0.30 to $0.23 for Q3, citing inflationary pressures, higher energy and supplier costs, and strategic price increases to offset cost headwinds.
3. AlphaVac Adoption and Growth
CEO James Clemmer highlighted that AlphaVac's sequential growth is driven by increased physician and hospital adoption, supported by APEX clinical data and approvals from hospital value analysis committees.
4. Supply Chain and Cost Management
CFO Stephen Trowbridge noted minimal China sourcing exposure, progress in the Costa Rica manufacturing transition, and proactive measures to mitigate tariff, inflation and sterilization shutdown risks.